Temperature Management on Postoperative Delirium
Launched by WANG HONGJIAN · May 6, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring how managing body temperature during hip surgery might affect the chances of developing delirium, which is a state of confusion that can occur after surgery, especially in older adults. Researchers want to see if keeping patients at the right temperature while they are under anesthesia can help reduce the risk of this condition.
To be eligible to participate in the trial, patients need to be at least 65 years old and scheduled for hip surgery. They should also be in good health overall, as determined by a medical assessment. However, individuals with certain neurological or psychiatric conditions, those who have had neurosurgery, or those with high body temperatures before surgery won't be able to join. If you decide to participate, you will be monitored closely throughout the process to ensure your safety and well-being. This study aims to better understand how temperature management could improve recovery for older patients after surgery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 65 years
- • Classified as American Society of Anesthesiologists I-III
- • Hip surgery patients who agreed to the study
- Exclusion Criteria:
- • Non-consent to participate
- • Diagnosed neurological or psychiatric disorders including schizophrenia, epilepsy, Parkinson's disease, or myasthenia gravis
- • Coma, dementia, or language impairment affecting communication and assessment
- • History of neurosurgery
- • Use of antipsychotic medication preoperatively
- • Body temperature exceeding 38°C within 24 hours before surgery.
About Wang Hongjian
Wang Hongjian is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative therapeutic solutions. With a focus on rigorous study design and ethical standards, the organization collaborates with healthcare professionals and research institutions to conduct high-quality clinical trials across various therapeutic areas. By leveraging cutting-edge methodologies and a patient-centered approach, Wang Hongjian strives to bring new treatments to market efficiently while ensuring the safety and well-being of participants. Their expertise and commitment to excellence position them as a trusted leader in the field of clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Xianwen Hu, PhD
Study Chair
The Second Hospital of Anhui Medical University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported